Regeneron Gets FDA Approval for EYLEA’s Pediatric Treatment
In another breakthrough for BCW Member Regeneron Pharmaceuticals, the U.S. Food and Drug Administration (FDA) has approved the company’s EYLEA® (aflibercept) Injection to treat preterm infants with retinopathy of prematurity (ROP). Following this first pediatric approval, EYLEA is now indicated to treat five retinal conditions caused by ocular angiogenesis.
“Retinopathy of prematurity is a leading cause of childhood blindness worldwide. Until now, the only FDA-approved treatment in common use was laser photocoagulation, a complex and lengthy procedure that permanently ablates retina tissue and is stressful not only for infant patients but also the family navigating a delicate time after a preterm birth,” said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron, and a principal inventor of EYLEA. “For the first time, physicians will now have an FDA approved medication in EYLEA to treat this heartbreaking disease in these smallest of patients. We thank the investigators and the many families who participated in the clinical trials.”
Each year in the U.S., between 1,100 to 1,500 infants develop ROP that is severe enough to require medical treatment. This rare eye disease often impacts infants who are born before 31 weeks of pregnancy have been completed or who weigh less than 3.3 lbs pounds at birth. “Regeneron’s trials investigating EYLEA in retinopathy of prematurity have advanced our understanding of how to treat this disease and provided a needed evidence-based treatment option to potentially help preterm infants preserve their vision,” said Jeff Todd, Chief Executive Officer of Prevent Blindness.
EYLEA is being jointly developed by Regeneron and Bayer.
More News
How are climate risks such as flooding, storm surge and extreme heat intersecting with economic vulnerability across Westchester County? New data from the New York Community Trust takes a closer look at the communities facing some of the greatest challenges and the organizations working to strengthen climate resilience, protect natural resources and prepare for a […]
The BCW joined a statewide coalition of businesses, trade associations and industry organizations is urging Governor Kathy Hochul to consider targeted revisions to the proposed One Fair Price Act (S.8623B/A.9349B), which recently passed both houses of the New York State Legislature. In a letter to the Governor, the coalition outlined concerns with the legislation as […]
MOUNT VERNON, NY (August 12, 2026) – In a milestone event for the City of Mount Vernon, BCW member Simone Development Companies & Stagg Group alongside officials from the State, County and City joined together yesterday to celebrate the “topping off” of QWest Towers, a new $158 million workforce housing development that is nearing completion […]
Become A Member
Join the county’s largest and most influential business organization today.
JOIN NOW!
Leave a Comment
You must be logged in to post a comment.